Several brokerages have updated their recommendations and price targets on shares of Catabasis Pharmaceuticals (NASDAQ: CATB) in the last few weeks: 2/6/2017 – Catabasis Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Catabasis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on […]